Abiopharma

🔍 Urist Marshall (Executive)

Company: Royalty Pharma plc (RPRX)

Report Date: 2026-01-16

Detailed Transactions and Holdings:

• Sold 20,000 shares of Class A Ordinary Shares at $39.5173 per share (Direct)
  Date: 2026-01-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 40,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-01-16 | Code: H | nature_of_ownership: By IRA | shares_owned_after: 19,020.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-01-16 | Code: H | shares_owned_after: 7,398.00

Footnotes:

• F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.37 to $39.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• REMARKS: In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.